Skip to main content

Table 1 Patients’ characteristics

From: Capecitabine and bevacizumab for non-resectable metastatic colorectal cancer patients: final results from phase II AIO KRK 0105 trial

Characteristic

n

%

Years

Age: median (range)

  

70 (49–86)

Sex

   

  Female

40

49

 

  Male

42

51

 

ECOG

   

  0

31

38

 

  1

43

52

 

  2

8

10

 

Comorbidity (clinically relevant)

  

(1 missing)

  yes

66

81

 

Primary tumor

   

  Colon

56

68

 

  Rectum

26

32

 

Resected primary tumor

66

80

 

Prior radiotherapy for rectal primary

12

15

 

Adjuvant chemotherapy

19

23

 

Metastases

  

(1 missing)

  synchronous metastases

58

72

 

  metastatic sites

   

  1

34

42

 

  >1

47

58

 

  liver metastases

65

80

 

Prognosis score acc. to Kohne et al.

  

(8 missing)

  low risk

64

86

 

  high risk

10

14

 
  1. Abbreviations: ECOG Eastern Cooperative Oncology Group performance status, n number.